Status:
COMPLETED
Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
LG Life Sciences
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
20-75 years
Phase:
NA
Brief Summary
This is an exploratory study on the metabolic endotoxemia associated with type 2 diabetes. The investigators will measure systemic endotoxin level and lipid level after ingestion of high fat diet to e...
Detailed Description
Study subjects will be allocated to either gemigliptin or placebo. After 4 weeks of treatment and 2 weeks of wash out period, all subjects will be switched to the opposite arm. The subjects will be t...
Eligibility Criteria
Inclusion
- Age from 20 to 75
- At least 6 months from the diagnosis of type 2 diabetes
- Current diabetes treatment: life style modification and/or metformin and/or sulfornylurea
- No change of the diabetes treatment (drug number and dossage) in recent 3 months
- HbA1c 6.5% to 10%
Exclusion
- Recent cardiovascular event in 6 months
- Concurrent use of statin or fibrate or ezetimibe
- Renal failure, chronic liver disease
- Pregnancy or lactation
- Use of other DPP-4 inhibitor or GLP-1 analogue in recent 3 months
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT02186080
Start Date
July 1 2014
End Date
July 1 2015
Last Update
April 21 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 110-744